Therapeutic concentrations of mitotane (o,p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model

Endocrinology

Volumn 151, Issue 6, 2010, Pages 2453-2461

  Zatelli, Maria Chiara ^a   Gentilin, Erica ^a   Daffara, Fulvia ^c   Tagliati, Federico ^a   Reimondo, Giuseppe ^c   Carandina, Gianni ^b   Ambrosio, Maria Rosaria ^a   Terzolo, Massimo ^c   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b S ANNA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; MITOTANE; THYROTROPIN; THYROTROPIN BETA SUBUNIT; THYROXINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LIOTHYRONINE; PROTIRELIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID FUNCTION; THYROTROPIN RELEASE; THYROXINE BLOOD LEVEL; TSH SECRETING CELL; ANIMAL; BLOOD; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MITOTANE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROTROPHS; THYROTROPIN; THYROTROPIN-RELEASING HORMONE; THYROXINE; TRIIODOTHYRONINE;

EID: 77954463079     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1404     Document Type: Article

References (34)

1. Bergenstal DM, Hertz R, Lipsett MB, Moy RH 1960 Chemiotherapy of adrenocortical cancer with o,p′DDD. Ann Intern Med 53:672
2. Young RB, Bryson MJ, Sweat ML, Street JC 1973 Complexing of DDT and o,p′DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem 4:585-591
3. Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC 1978 o,p′-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 42:2177-2181
4. Allolio B, Fassnacht M 2006 Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027-2037
5. Libè R, Fratticci A, Bertherat J 2007 Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13-28
6. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP 2005 Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667-680
7. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A 2007 Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380
8. Pommier RF, Brennan MF 1992 An eleven-year experience with adrenocortical carcinoma. Surgery 112:963-970; discussion 970-971
9. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947-951
10. Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D 1981 Blood levels of o,p′-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol 7:51-54
11. Terzolo M, Pia A, Berruti A, Osella G, Alì A, Carbone V, Testa E, Dogliotti L, Angeli A 2000 Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 85:2234-2238
12. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M 2001 Impact of monitoring plasma1,1-dichloro- diphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385-1392
13. Lee JE 2007 Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 357:1256-1258, author reply 1259
14. Daffara F, De Francia S, Reimondo G, Zaggia B, Arosio M, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A, Terzolo M 2008 Prospective evaluation of mitotane toxicity in adrenalcortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043-1053
15. van Seters AP, Moolenaar AJ 1991 Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol 124:526-533
16. Marshall JS, Tompkins LS 1968 Effect of o, p′- DDD and similar compounds on thyroxinee binding globulin. J Clin Endocrinol Metab 28:386-392
17. De Francia S, Pirro E, Zappia F, De Martino F, Sprio AE, Daffara F, Terzolo M, Berruti A, Di Carlo F, Ghezzo F 2006 A new simple HPLC method for measuring mitotane and its two principal metabolites. Tests in animals and mitotane-treated patients. J Chromatogr B Analyt Technol Biomed Life Sci 837:69-75
18. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC 2002 Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 297:828-834
19. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC 2001 Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab 86:2161-2169
20. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC 2003 Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. J Clin Endocrinol Metab 88:2797-2802
21. Magner JA 1990 Thyroid-stimulating hormone: biosynthesis, cell biology, and bioactivity. Endocr Rev 11:354-385
22. Shupnik MA, Ridgway EC, Chin WW 1989 Molecular biology of thyrotropin. Endocr Rev 10:459-475
23. Pierce JG, Parsons TF 1981 Glycoprotein hormones: structure and function. Annu Rev Biochem 50:465-495
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F 2002 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:research0034.1-research0034.11
25. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
26. Kim KK, Song SB, Kang KI, Rhee M, Kim KE 2007 Activation of the thyroid-stimulating hormone β-subunit gene by LIM homeodomain transcription factor Lhx2. Endocrinology 148:3468-3476
27. Nader N, Raverot G, Emptoz-Bonneton A, Déchaud H, Bonnay M, Baudin E, Pugeat M 2006 Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 91:2165-2170
28. Kailajärvi M, Takala T, Grönroos P, Tryding N, Viikari J, Irjala K, Forsström J 2000 Reminders of drug effects on laboratory test results. Clin Chem. 46:1395-1400
29. Dong BJ 2000 How medications affect thyroid function. West J Med 172:102-106
30. Fang VS 1979 Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)- 2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture. Cancer Res 39:139-145
31. Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, Piergrossi P, Brunetti E, Simmaco M, Toscano V 2008 Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr Relat Cancer 15:1-10
32. Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, Toscano V, Stigliano A 2008 Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer 15:623-634
33. Pushkarev VM, Tronko ND, Kostyuchenko NN, Mikosha AS 2007 Effect of o,p′-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex. Ukr Biokhim Zh 79:44-49
34. Yusta B, Alarid ET, Gordon DF, Ridgway EC, Mellon PL 1998 The thyrotropin β-subunit gene is repressed by thyroid hormone in a novel thyrotrope cell line, mouse TαT1 cells. Endocrinology 139:4476-4482